Immunome Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
18702 N. CREEK PARKWAY, BOTHELL, WA, 98011
Mailing Address
18702 N. CREEK PARKWAY, BOTHELL, WA, 98011
Phone
610-321-3700
Fiscal Year End
1231
EIN
770694340
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 10-K Annual financial report | March 3, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
Annual Reports
10-K
March 3, 2026
- Lead ADC candidate, IMM-101, successfully completed Phase 1 clinical trial, paving the way for a planned Phase 2 study.
- Preclinical ADC candidate IMM-202 demonstrated strong efficacy, with an Investigational New Drug (IND) application expected in mid-2026.
Insider Trading
STRONG SELL
7 insiders
14 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.